^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IGLV3 21R110

    i
    Other names: IGLV3-21, Immunoglobulin Lambda Variable 3-21, Ig Lambda Chain V-III Region LOI, Ig Lambda Chain V-VII Region MOT, Ig Lambda Chain V-V Region DEL, IGLV321, V2-14
    Entrez ID:
    28796
    2years
    Mutation-specific CAR T cells as precision therapy for IGLV3-21 expressing high-risk chronic lymphocytic leukemia. (PubMed, Nat Commun)
    We further demonstrate in two humanized mouse models lack of cytotoxicity towards human B cells. These data provide the basis for advanced approaches of resistance-preventive and biomarker-guided cellular targeting of functionally relevant lymphoma driver mutations sparing normal B cells.
    Journal • CAR T-Cell Therapy
    |
    IGLV3-21 (Immunoglobulin Lambda Variable 3-21)
    |
    IGLV3 21R110
    2years
    Telomere Length and DNA Methylation Epitype Both Provide Independent Prognostic Information in CLL Patients; Data from the UK CLL4, Arctic and Admire Clinical Trials (ASH 2023)
    In conclusion, by assessing the individual contribution of DME and TL to disease survival, we found that both variables offer valuable independent prognostic information when included in statistical models with poor-risk genomic lesions. TL and DME could help identify IGHV-mutated patients destined to respond poorly to (immuno-)chemotherapy, that might be more favourably treated with targeted agents.
    Clinical • Epigenetic controller
    |
    TP53 (Tumor protein P53) • SF3B1 (Splicing Factor 3b Subunit 1) • IGH (Immunoglobulin Heavy Locus) • IGLV3-21 (Immunoglobulin Lambda Variable 3-21)
    |
    TP53 mutation • Chr del(11q) • SF3B1 mutation • IGH mutation • IGLV3 21R110
    over2years
    IGLV3-21R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial (ASH 2023)
    IGLV3-21R110 was identified as an independent prognostic factor for shorter EFS in early stage CLL with intermediate/high risk score and was associated with reduced ibrutinib efficacy in the CLL12 trial.
    Clinical • IO biomarker
    |
    TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • SF3B1 (Splicing Factor 3b Subunit 1) • IGH (Immunoglobulin Heavy Locus) • B2M (Beta-2-microglobulin) • XPO1 (Exportin 1) • IGLV3-21 (Immunoglobulin Lambda Variable 3-21) • NFKBIE (NFKB Inhibitor Epsilon)
    |
    TP53 mutation • Chr del(11q) • SF3B1 mutation • IGH mutation • Chr del(17p) + Chr del(11q) • IGLV3 21R110 • XPO1 mutation
    |
    Imbruvica (ibrutinib)